Immunome (IMNM) Prices 10M Share Offering at $20/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- S&P 500 up, Nasdaq at record high as megacap tech stocks rise
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Paramount Skydance to close WBD deal, change ticker to SKYD
Immunome Announces Pricing of Public Offering of Common Stock
February 13, 2024 10:38 PM ESTBOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Immunome) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share. All of the shares are to be sold by Immunome.
The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $200.0 million. In addition, Immunome has granted the underwriters a 30-day option to purchase up to an... More



